

RCE of Application No.: 09/810,883
Attorney Docket No.: TNX 98-08-01
Customer No.: 26839

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-46 (Canceled)

47. (NEW) A bispecific antibody, or a binding fragment thereof, comprising a first determinant that binds to an Immunoreceptor Tyrosine-Based Activation Module (ITAM), wherein said ITAM is selected from the group consisting of BCR, FcεRI, FcγRI, FcγRIIA, FcγRIIA, and TCR, and a second determinant that binds to an Immunoreceptor Tyrosine-Based Inhibition Module (ITIM), wherein said ITIM is selected from the group consisting of FcγRIIB, FcγRIII, and FcεRII.
48. (NEW) The bispecific antibody of claim 47 or a binding fragment thereof, comprising antigen-binding regions from two different antibodies.
49. (NEW) The bispecific antibody of claim 47, wherein the ITIM is FcεRII.
50. (NEW) The bispecific antibody of claim 47, wherein the ITIM is FcγRII.
51. (NEW) A composition comprising the bispecific antibody of claim 47, or a binding fragment thereof, and a physiologically acceptable carrier, excipient, or diluent.
52. (NEW) The bispecific antibody of claim 47, wherein at least one determinant is humanized, human, chimeric, or an ScFv.
53. (NEW) A method of inhibiting the release of TNF-α from a mast cell or a basophil comprising administering the bispecific antibody of claim 47, or a binding fragment thereof.
54. (NEW) A method of inhibiting the release of histamine from a mast cell or a basophil comprising administering the bispecific antibody of claim 47, or a binding fragment thereof.
55. (NEW) The method of claim 53, wherein the bispecific antibody concentration ranges from 0.1 to 1 μg/ml.
56. (NEW) A method of ameliorating an allergic disease or condition in a mammal comprising administering the bispecific antibody of claim 47, or a binding fragment thereof.